Although the association of the luminal phenotype with Tamoxifen and ESR1 expression level provides an additional validation of the specificity of the methodology, a more pressing question in the context of breast cancer therapy is the basal phenotype since effective treatments for this group of patients are limited. The gene discussed is ESR1; the disease is breast cancer.